Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Athenex Pharma Solutions, an Athenex, Inc. Company, Launches Compounded Vasopressin Injection in Ready-to-Use Premix IV Bags | ||
By: Nasdaq / GlobeNewswire - 13 Aug 2018 | Back to overview list |
|
BUFFALO, N.Y., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the launch of compounded Vasopressin Injection in ready-to-use premix IV bags through its subsidiary Athenex Pharma Solutions (APS). APS is focused on applying pharmaceutical cGMP expertise to the 503(B) market to address hospital needs for high-quality outsourced compounding services. Vasopressin Injection products launched today and available to order from Athenex include:
Per IQVIA sales data, the Vasopressin market in the United States exceeds $400 million annually. Jeffrey Yordon, Athenex’s Chief Operating Officer and President of APS, commented, “We are delighted to introduce our Vasopressin products to the US market in multiple, ready-to-use premix IV bag presentations. Our launch of Vasopressin Injection in ready-to-use premix IV bags underscores Athenex’s ongoing commitment to broadening our 503(B) portfolio through customer-focused innovation.” Athenex’s products emphasize quality and can help to enhance patient safety. cGMP processes are followed for each of Athenex’s products, and a Certificate of Analysis is provided for each batch of 503B products so customers are able to see measurable results from repeatable tests. Additionally, Athenex’s AccuraSEE Packaging and Labeling, a proprietary, patent-pending and highly differentiated approach to product packaging and labeling, features a unique label design for every product to give caregivers accurate information and help to reduce the risk of medication errors. APS is committed to developing and providing a broad portfolio of quality injectable products compliant with the FDA Act Section 503(B). APS’ FDA-inspected 503(B) facility is located in Clarence, NY. The APS product portfolio is available at www.athenexpharma.com. CONTACTS: Investor Relations: |
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |